Symplicity Spyral™ renal denervation system
for hypertension
Symplicity Spyral™ renal denervation (RDN) system is used during the Symplicity™ blood pressure procedure for the treatment of hypertension.
Introducing a procedure to treat hypertension
During the Symplicity™ blood pressure procedure, an interventionalist uses the Symplicity Spyral™ RDN system to supply precisely controlled and targeted radiofrequency (RF) energy to the renal nerves, safely disrupting the overactive sympathetic signaling between the kidneys and brain to help reduce blood pressure.1–3
30,000 patients around the globe have been treated with the Symplicity™ RDN system.4
Symplicity Spyral™ multi-electrode renal denervation catheter
- One catheter size fits vessels 3–8 mm5
- 4 F catheter,† compatible with 6 F guide catheter, 0.014" guidewire
- Easy-to-use, plug-and-play design
- Nonocclusive design allows for continuous blood flow to naturally protect the vessel wall1
Symplicity G3™ renal denervation RF generator
- Unique, real-time, and responsive algorithm automatically adjusts power by monitoring temperature and impedance for safe energy distribution1
- Multi-electrode, helical design covers four quadrants simultaneously for a circumferential ablation1,5
- Radiofrequency energy preferentially heats fat tissue where renal nerves are located and avoids nontarget structures‡,6
- Only the Symplicity Spyral™ RDN system allows for denervation throughout the renal anatomy with a single catheter, including the distal branches,5 where late arriving nerves are accessible and total nerve density is highest7,8
Proven to deliver significant, safe, and sustained blood pressure reductions2,3,9,10
- Multiple randomized, sham-controlled clinical trials
- Real-world experience with more than 5,000 patients enrolled in the SPYRAL HTN clinical program§,◊,2,3,11
The science of renal denervation
Explore the science of RDN
Watch a short animation that explains the mechanism of action for RF renal denervation with the Symplicity Spyral™ system.
Ordering information
Symplicity Spyral™ system products
| Item number | Description |
|---|---|
|
RDN016 |
Symplicity Spyral™ multi-electrode RDN catheter |
|
RDNG3A |
Symplicity™ G3 generator, supplied standard with remote control |
|
RDN019 |
Mobile cart for Symplicity™ G3 generator (optional accessory) |
Additional products used during the Symplicity™ procedure
| Item number | Description |
|---|---|
|
SB6RDND1K |
Sherpa NX™ balanced 6 Fr 55 cm guide catheter with RDND1 curve |
|
LA6IMAK |
Launcher™ 6 Fr 55 cm guide catheter with IMA curve |
|
SB6IMAK |
Sherpa NX™ balanced 6 Fr 55 cm guide catheter with IMA curve |
|
E7507 and |
Dispersive electrode for RDNG3A: Compatible with ValleyLab Polyhesive™ adult patient return electrode |
Resources
Review clinical evidence.
The Symplicity Spyral™ RDN system is backed by multiple sham-controlled trials and a real-world registry.
See how renal denervation can help.
Learn more about the turning point in hypertension care and how it can help enhance treatment strategies.
† Catheter dimension of 0.052" is average maximum diameter determined during design verification. Upper bound allowable is 0.061".
‡ Preclinical data may not be indicative of clinical performance.
§ Includes Symplicity Spyral™ and Flex™ catheters.
◊ Study follow-up is ongoing. Data does not represent follow-up for all patients.
References
1
Coates P, Tunev S, Trudel J, Hettrick DA. Time, temperature, power, and impedance considerations for radiofrequency catheter renal denervation. Cardiovasc Revasc Med. 2022;42:171–177.
2
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham controlled trial. Lancet. 2020;395(10234):1444–1451.
3
Kandzari D, Townsend R, Kario K, et al. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. J am coll cardiol. 2023;82(19):1809–1823.
4
Based on RDN catheter historical data, Feb 2025. Data includes both Symplicity™ Flex and Symplicity Spyral™. Medtronic data on file.
5
Medtronic Symplicity Spyral multi-electrode renal denervation catheter and Symplicity G3 generator instructions for use.
6
Sato Y, Sharp A, Mahfoud F, et al. Translational value of preclinical models for renal denervation: a histological comparison of human versus porcine renal nerve anatomy. Eurointervention. 2023;18(13):e1120–e1128.
7
García-Touchard A, Maranillo E, Mompeo B, Sañudo JR. Microdissection of the human renal nervous system: Implications for performing renal denervation procedures. Hypertension. 2020;76(4):1240–1246.
8
Struthoff H, Lauder L, Hohl M, et al. Histological examination of renal nerve distribution, density, and function in humans. EuroIntervention. 2023;19(7):612–620.
9
Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399(10234):1401–1410.
10
Mahfoud F, et al. Outcomes following radiofrequency renal denervation according to antihyptensive medications: subgroup analysis of the Global SYMPLICITY Registry DEFINE. EuroPCR 2023.
11
Mahfoud F, Mancia G, Schmieder RE, et al. Outcomes Following Radiofrequency Renal Denervation According to Antihypertensive Medications: Subgroup Analysis of the Global SYMPLICITY Registry DEFINE. Hypertension. 2023;80(8):1759–177.